BVF Inc. IL lifted its holdings in shares of Molecular Partners AG (NASDAQ:MOLN - Free Report) by 205.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,353,968 shares of the company's stock after purchasing an additional 910,747 shares during the quarter. BVF Inc. IL owned about 3.35% of Molecular Partners worth $6,458,000 as of its most recent filing with the SEC.
Analysts Set New Price Targets
Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a report on Tuesday, March 11th. They set an "outperform" rating and a $12.00 target price on the stock.
Get Our Latest Research Report on Molecular Partners
Molecular Partners Trading Up 3.5 %
NASDAQ:MOLN traded up $0.14 during midday trading on Friday, reaching $4.10. The company had a trading volume of 2,754 shares, compared to its average volume of 20,931. Molecular Partners AG has a 12-month low of $3.36 and a 12-month high of $12.70. The firm has a market capitalization of $165.54 million, a price-to-earnings ratio of -1.91 and a beta of 1.15. The stock's fifty day simple moving average is $4.05 and its 200-day simple moving average is $4.94.
Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. As a group, sell-side analysts expect that Molecular Partners AG will post -1.93 EPS for the current year.
Molecular Partners Company Profile
(
Free Report)
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
See Also
Before you consider Molecular Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molecular Partners wasn't on the list.
While Molecular Partners currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
